Larimar Therapeutics (LRMR) Cash & Current Investments: 2013-2020
Historic Cash & Current Investments for Larimar Therapeutics (LRMR) over the last 7 years, with Sep 2020 value amounting to $102.3 million.
- Larimar Therapeutics' Cash & Current Investments rose 24.76% to $102.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $323.9 million, marking a year-over-year decrease of 18.28%. This contributed to the annual value of $44.1 million for FY2019, which is 62.68% down from last year.
- As of Q3 2020, Larimar Therapeutics' Cash & Current Investments stood at $102.3 million, which was down 10.01% from $113.7 million recorded in Q2 2020.
- Over the past 5 years, Larimar Therapeutics' Cash & Current Investments peaked at $166.2 million during Q1 2016, and registered a low of $44.1 million during Q4 2019.
- Its 3-year average for Cash & Current Investments is $92.1 million, with a median of $91.7 million in 2019.
- As far as peak fluctuations go, Larimar Therapeutics' Cash & Current Investments spiked by 80.04% in 2016, and later plummeted by 62.68% in 2019.
- Larimar Therapeutics' Cash & Current Investments (Quarterly) stood at $129.2 million in 2016, then decreased by 21.01% to $102.1 million in 2017, then climbed by 15.69% to $118.1 million in 2018, then slumped by 62.68% to $44.1 million in 2019, then rose by 24.76% to $102.3 million in 2020.
- Its last three reported values are $102.3 million in Q3 2020, $113.7 million for Q2 2020, and $63.9 million during Q1 2020.